The first nationally-certified primary stroke center in Oregon, and a leader in accessible, comprehensive, state-of-the-art stroke care, education and research
The following study is testing an investigational medication to help prevent further heart attacks or stroke in people with atherosclerotic disease.
TRA 2°P – TIMI 50: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard of care in subjects with a history of atherosclerotic disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (Protocol No. P04737).
This study is recruiting patients who have been diagnosed with a myocardial infarction (MI) or ischemic cerebrovascular disease (stroke) more than two weeks prior to study start, but less than 12 months ago. Patients are randomly assigned (by chance) to the investigational medication (not approved by the U.S. Food and Drug Administration) called SCH 530348 that is taken daily by mouth, or placebo (inactive look-alike tablet). Participation will last approximately four years.
All required study visits, tests and the medications will be provided at no cost.
Contact us Providence Stroke Center
9427 S.W. Barnes Road, Suite 595
Portland, OR 97225
503-216-2346 BrainInstitute@Providence.org
Sponsor: Schering-Plough Research Institute Principal investigator: Ted Lowenkopf, M.D.
The study described below involves a treatment for hospitalized patients who experienced an intraventricular hemorrhage. (Enrollment for this inpatient trial is decided between physician and patient at the hospital.)
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III (CLEAR III). A Multicenter, International, Double-Blind, Randomized Study Comparing the Use of EVD Combined with rt-PA to EVD Combined with Placebo for the Treatment of Intraventricular Hemorrhage.
The primary objective is to define precisely the long-term effects of lysing ventricular blood clots with rt-PA on the functional outcomes of cerebral hemorrhage patients. Study duration is one year.
All required study visits, tests and the medications will be provided at no cost.
Sponsor:Johns Hopkins University Principal investigator:David Antezana, M.D., and Lisa Yanase, M.D.
If you are interested in this study, please contact Summer Carter, clinical research coordinator, at 503-216-1034. For more information, please visit the CLEAR III Web site.
Click here for more information on other clinical trials offered through Providence Brain Institute.
